We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Iovance Biotherapeutics Inc | NASDAQ:IOVA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.24 | 1.76% | 13.87 | 13.87 | 13.88 | 14.23 | 13.75 | 13.80 | 2,272,188 | 17:47:38 |
By Mary de Wet
Iovance Biotherapeutics shares rose 15% in after-hours trade Friday after the company's biologics license application for lifileucel to treat advanced skin cancer was approved by the Food and Drug Administration.
The stock was at $8.67 after closing at $7.55 in regular trade. Shares are up 18% for the year.
"The FDA is not currently planning to hold an advisory committee meeting to discuss this application and, after a preliminary review, has not at this time identified any potential review issues," the San Carlos, Calif.-based company said.
Lifileucel is a tumor infiltrating lymphocyte therapy intended for patients with advanced melanoma who progressed on or after prior anti-PD-1/L1 therapy and targeted therapy, Iovance said.
There are no FDA-approved therapies to treat these patients, the company said.
With the biologics license application approved, Iovance can get a license to market lifileucel in the U.S.
Write to Mary de Wet at mary.dewet@dowjones.com
(END) Dow Jones Newswires
May 26, 2023 18:50 ET (22:50 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Iovance Biotherapeutics Chart |
1 Month Iovance Biotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions